Selected References:

• Coppola D, et al. 2007. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf; 30(3):247-264. 
• Cho H, et al. 2025. Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns. J Affect Disord; 373:495-504. 
• Damkier P and Videbech P. 2018. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. CNS Drugs; 32:351-366. 
• Eberhard J., et al. 2007. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatrica Scandinavica; 115(4), 268-276. 
• Ennis ZN and Damkier P. 2014. Pregnancy Exposure to Olanzapine, Quetiapine, Risperidone, Aripiprazole and Risk of Congenital Malformation. A Systemic Review. Basic & Clinical Pharmacology & Toxicology; 116:315-320. 
• Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5 -year study. Am J Obstet Gynecol; 190:435-441. 
• Habermann F, et al. 2013. Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study. J Clin Psychopharmacol; 33:453-462. 
• Huybrechts KF, et al. 2016. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry; 73(9): 938-946. 
• National Library of Medicine. 2026. Drug labeling information (section 8.2). DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6767972-2d3f-482b-80bd-ac93e28fdd05&type=display#section-8.2 
• McAllister-Williams RH, et al. 2017.  British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.  J Psychopharmacol; 31(5): 519-552. 
• Park Y, et al. 2018. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Am J Psychiatry; 175(6):564-574. 
• Petersen I, et al. 2016. Risks and Benefits of Psychotropic Medication in Pregnancy: Cohort Studies based on UK Electronic Primary Care Health Records. Health Technol Assess; 20:1-176 
• Straub L, et al. 2022. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. JAMA Intern Med; 182(5):522-533.  
• Uguz F. 2016. Second-Generation Antipsychotics During the Lactation Period. J Clin Psychopharmacol; 36(3):244-252. 
• Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. Breastfeed Med; 14:683–684. 
• Vigod SN, et al. 2015. Antipsychotic Drug Use In Pregnancy: High Dimensional, Propensity Matched, Population Based Cohort Study. BMJ; 350:h2298. 
• Wang E, et al. 2025. Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes. CNS Drugs; 39(1):1-22. 

Selected References:

• ACOG Committee Opinion No 804. 2020. Physical Activity and Exercise During Pregnancy and the Postpartum Period. Obstet Gynecol; 135(4):e178-188.  
• ACOG. 2022. Exercise During Pregnancy. Frequently asked questions. Available at: https://www.acog.org/womens-health/faqs/exercise-during-pregnancy [Accessed 3/2026]. 
• Artal R. 2016. Exercise in Pregnancy: Guidelines. Clin Obstet Gynecol. 59(3):639-644. 
• Barakat R, Perales M. 2016. Resistance Exercise in Pregnancy and Outcome. Clin Obstet Gynecol. 59(3):591-599. 
• Claiborne, A, et al. 2023. A narrative review of exercise dose during pregnancy. Birth Defects Res. 115(17):1581–1597. 
• Clapp III JF, et al. 1999. Neonatal behavioral profile of the offspring of women who continued to exercise regularly throughout pregnancy. Am J Obstet Gynecol. 180(1):91-94.  
• Clapp III JF, et al. 2002. Continuing regular exercise during pregnancy: Effect of exercise volume on fetoplacental growth. Am J Obstet Gynecol. 186(1):142-147. 
• Cordero Y, et al. 2015. Exercise is associated with a reduction in gestational diabetes mellitus. Med Sci Sports Exerc. 47(7):1328-1333. 
• Fly AD, et al. 1998. Major mineral concentrations in human milk do not change after maximal exercise testing. Am J Clin Nutr. 68(2):345-349. 
• Kennelly MM, et al. 2002. Exercise-related changes in umbilical and uterine artery waveforms as assessed by Doppler ultrasound scans. Am J Obstet Gynecol. 187(3):661-666. 
• Kennelly MM, et al. 2002. Fetal heart rate response to strenuous maternal exercise: not a predictor of fetal distress. Am J Obstet Gynecol. 187(3):811-816. 
• Kołomańska-Bogucka D, Mazur-Bialy AI. 2019. Physical Activity and the Occurrence of Postnatal Depression-A Systematic Review. Medicina (Kaunas). 55(9):560.  
• Lederman SA, et al. 1999. Maternal body fat and water during pregnancy: Do they raise infant birth weight? Am J Obstet Gynecol; 180(1):235-240. 
• Gascoigne EL, et al. 2023. Physical activity and pregnancy outcomes: an expert review. Am J Obstet Gynecol MFM; 5(1):100758. 
• Gavard J & Artal R. 2008. Effect of Exercise on Pregnancy Outcome. Clin Obstet Gynecol; 51(2):467-480.  
• Gregg VH & Ferguson JE. 2017. Exercise in Pregnancy. Clin Sports Med; 36(4):741-752. 
• Greydanus DE & Patel DR. 2002. The female athlete. Before and beyond puberty. Pediatr Clin North Am. 49(3):553-580. 
• Hicks LE, et al. 2025. Prenatal exercise and its effects on postpartum mental health: systematic review and meta-analysis. Arch Womens Ment Health. 28(3):515-524. 
• Madsen M, et al. 2007. Leisure time physical exercise during pregnancy and the risk of miscarriage: a study within the Danish National Birth Cohort. BJOG; 114(11):1419-1426. 
• McLachlan ML, et al. 2026. Case Report: Hyperlactation and Sport Performance in an Elite Marathon Runner. Clin J Sport Med. Jan 22. doi: 10.1097/JSM.0000000000001399. Online ahead of print. 
• Minguez-Alarcon L, et al. 2014. Physical activity is not related to semen quality in young healthy men. Fertil Steril. 102(4): 1103-1109.  
• Moolyk AN, et al. 2025. Maternal and fetal responses to acute high-intensity resistance exercise during pregnancy. Br J Sports Med. 59(3):159-166.  
• Mottola MF, et al. 2018. No. 367-2019. Canadian Guideline for Physical Activity throughout Pregnancy. J Obstet Gynaecol Can; 40(11):1528-1537. 
• Mussawar M, et al. 2023. The effect of physical activity on fertility: a mini-review. F S Rep; 4(2):150-158. 
• Oxnard KL, et al. 2026. Patterns in exercise behaviour across pregnancy: a retrospective cohort study of physically active individuals from pre-conception to postpartum. Eur J Appl Physiol. Feb 25. doi: 10.1007/s00421-026-06160-6. Online ahead of print. 
• Prevett C, et al. 2025. Resistance training in pregnancy: systematic review and meta-analysis of pregnancy, delivery, fetal and pelvic floor outcomes and call to action. Br J Sports Med. 59(16):1173-1182. 
• Price BB, et al. 2012. Exercise in pregnancy: effect on fitness and obstetric outcomes-a randomized trial. Med Sci Sports Exerc; 44(12):2263-2269. 
• Redondo-Delgado P, et al. 2025. Effects of strength training on quality of life in pregnant women: A systematic review. Acta Obstet Gynecol Scand. 104(7):1231-1243. 
• Saccone G, et al. 2026. Exercise in Pregnancy and Risk of Postpartum Depression: A Randomised Controlled Trial. BJOG. 133(2):211-217. 
• Sanabria-Martínez G, et al. 2019. Effects of physical exercise during pregnancy on mothers’ and neonates’ health: a protocol for an umbrella review of systematic reviews and metaanalysis of randomised controlled trials. BMJ Open; 9(9):e030162. 
• Sobal J & Marquart LF. 1994. Vitamin/mineral supplement use among athletes: a review of literature. Int J Sport Nutr; 4(4):320-334. 
• Sujan MJ, et al. 2025. Time restricted eating and exercise training before and during pregnancy for people with increased risk of gestational diabetes: single centre randomised controlled trial (BEFORE THE BEGINNING). BMJ. 390:e083398.  
• Stafne SN, Salvesen et al. 2012. Regular exercise during pregnancy to prevent gestational diabetes: a randomized controlled trial. Obstet Gynecol. 119(1):29-36. 
• Tomic V, et al. 2013. The effect of maternal exercise during pregnancy on abnormal fetal growth. Croat Med J. 54(4):362-368. 
• U.S. Department of Health and Human Services. 2018. Physical activity guidelines for Americans. 2nd ed. Washington, DC: DHHS. Available at: https://health.gov/paguidelines/second-edition/. [Accessed March 2026].  
• Zourtadani A, et al. 2015. The effect of physical exercise on postpartum fitness hormone and lipid levels: a randomized controlled trial in primiparous, lactating women. Arch Gynecol Obstet 291(3): 525-530. 

Selected References:

• Ambresin G, et al. 2004. Olanzapine excretion into breast milk: a case report. J Clin Psychopharmacol; 24(1):93-95. 
• Aydin B, et al. 2015. Olanzapine and quetiapine use during breastfeeding: Excretion into breast milk and safe breastfeeding strategy. J Clin Psychopharmacol; 35:206-208. 
• Betcher HK, et. al 2020. Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. J Womens Health 29(3):310-318. 
• Brunner E, et al. 2013. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacology & Toxicology, 14, 1-8.  
• Croke S, et al. 2003. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol; 5:243-247. 
• Damkier P, et al. 2018. The safety of second-generation antipsychotics during pregnancy: a clinically-focused review. CNS Drugs 32:351-366. 
• Einarson A & Boskovic R. 2009. Use and safety of antipsychotics during pregnancy. Journal of Psychiatric Practice; 15, 183-192.  
• Eli Lilly and Company. 2025. Zyprexa product label. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341. Accessed 31 March 2026.  
• Ellfolk M, et al. 2021. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol. 2021; 77(11): 1737–1745. 
• Ennis ZN, et al. 2014. Pregnancy exposure to Olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations: A systemic review.  Basic & Clinical Pharmacology & Toxicology; 116(4), 315-320.   
• Friedman SH, et al. 2017. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int J Psychiatry Med; 51(6): 521-533. 
• Gilad O, et al. 2011. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeeding Medicine; 6, 55-58. 
• Habermann F, et al. 2013. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol; 33(4):453-462.  
• Heinonen E, et al. 2022. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register‑Based Cohort Study in Sweden. CNS Drugs; 36:529-
• 539. Huybrechts KF, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatr; 73(9):938-946. 
• Johnson KC et al. 2012. Prenatal antipsychotic exposure and neuromotor performance during infancy.  Arch Gen Psychiatry; 69(8):787-794. Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy.  Pharmaceuticals. 6(10): 1221-1286. 
• Kolli P, et al. 2023. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions. Pharmgenomics Pers Med; 16:1097-1108. 
• Manouilenko I, et al. 2018. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report. Arch Womens Ment Health; 21(5):587-589 
• McKenna K, et al. 2005. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. Journal of Clinical Psychiatry; 4, 444-449.  
• Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. J Clin Psychiat; 66:269-270. 
• Newport DJ, et al 2007. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry; 164(8):1214-20.  
• Pacchiarotti I, et al. 2016. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. Eur Neuropsychopharmacol; 26:1562-1578. 
• Park Y, et al. 2018. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Psychiatry; 175(6):564-574. 
• Reutfors J, et al. 2020 Antipsychotic drug use in pregnancy: A multinational study from 10 countries. Schizophr Res; 220:106-115. 
• Rubakowski J, et al. 2019. Recommendations of the Poliksh Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. Psychiatr Pol; 53(2):263-276. 
• Shao P, et al. 2015. Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis. PLoS One; 10(4). 
• Teodorescu A, et al. 2017. Dilemma of treating schizophrenia during pregnancy: a case series and a review of literature. BMC Psychiatry; 17(1):311.  
• Vigod SN, et al. 2015. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ; 350:h2298.  

Selected References:

• Aljazaf K, et al. 2003. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. Br J Clin Pharmacol; 56(1):18- 24.  
• Anastasio GD, et al. 1992. Fetal tachycardia associated with maternal use of pseudoephedrine, an over-the-counter oral decongestant. J Am Board Fam Pract; 5(5):527-528.  
• Dor S, et al. 2025. Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population-based cohort of pregnancies. Br J Clin Pharmacol; 91(6):1834-1841. 
• Eglash A. 2014. Treatment of maternal hypergalactia. Breastfeed Med; 9:423-425. 
• Findlay JW, et al. 1984. Pseudoephedrine and triprolidine in plasma and breast milk of nursing mothers. Br J Clin Pharmacol; 18(6):901-906.  
• Głowacka K, et al. 2021. Pseudoephedrine-Benefits and Risks. Int J Mol Sci; 22(10):5146.  
• Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, MA: John Wright-PSG. pp 345-356.  
• Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol; 168(5):1393-1399.  
• Miller RK. 1992. From the pages of Teratology: vitamin A to pseudoephedrine issues in patient counseling. Teratology; 45(4):341-343.  
• Pseudoephedrine Drug Label. 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1056d9da-8a3f-4b7a-878e-7f8d45d298cd&audience=consumer. Accessed 24 March 2026. 
• Rosa F. 1993. Personal communication. Cited in: Briggs GG, et al. 2005. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Seventh Edition. Baltimore, MD: Williams & Wilkins.  
• Schatz M, et al. 1997. Asthma and allergy in pregnancy. Clin Perinatol; 24(2):407-432.  
• Smith CV, et al. 1990. Effect of a single dose of oral pseudoephedrine on uterine and fetal Doppler blood flow. Obstet Gynecol; 76(5 Pt 1):803-806.  
• Smith J, et al. 1994. Drugs of choice for pregnant women. In: Koren G. Maternal-fetal Toxicology. A Clinician’s Guide. 1994. Second Edition. New York NY: Marcel Dekker Inc.  
• Soussan C, et al. 2014. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol; 70:1361-1366. 
• The American College of Obstetricians and Gynecologists (ACOG).  2025. “Ask ACOG: What medicine can I take for allergies while I’m pregnant?” Available at: https://www.acog.org/womens-health/experts-and-stories/ask-acog/what-medicine-can-i-take-for-allergies-while-im-pregnant. Accessed 24 March 2026.  
• The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). 2000. The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol; 84(5):475-480. 
• Torfs CP, et al. 1996. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 54(2):84-92.  
• Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol; 178(2):198-208. 
• Werler MM, et al. 2003. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology; 14(3):349-354.  
• Werler MM, et al. 1992. First trimester maternal medication use in relation to gastroschisis. Teratology; 45(4):361-367.  
• Werler MM, et al. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol; 155(1):26-31.  
• Werler MM, et al. 2004. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol; 70(6):389-395.  

Selected References:

• Anderson KN, et al., 2020. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA psychiatry, 77(12):1246–1255.  
• Bellantuono C, et al. 2015. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol. 30(3):143-51. 
• Berard A, et al. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the Quebec Pregnancy Cohort. BMJ Open;7: e013372. 
• Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry. 65(9):1228-1234. 
• Chambers CD, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 354:579-587. 
• Dandjinou M, et al. 2019. Antidepressant use during pregnancy and risk of gestational diabetes mellitus: a nested case-control study. BMJ Open 9(9): e025908. 
• Das N, Chadda RK. 2020. Hyperprolactinemic galactorrhea associated with cefpodoxime in a patient with recurrent depressive disorder on venlafaxine monotherapy: A case report. J Clin Psychopharmacol. 40:635–6. 
• Desai PH, et al. 2019. Risk of congenital heart disease in newborns with prenatal exposure to anti-depressant medications. Cureus 11(5): e4673. 
• de Santi F, et al. 2021. Venlafaxine-induced damage to seminiferous epithelium, spermiation, and sperm parameters in rats: A correlation with high estrogen levels. Andrology. 9(1):297-311.  
• Einarson A, et al. 2001. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 158(10):1728-1730. 
• Ferreira E, et al. 2007. Effects of selective reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 119(1):52-59. 
• Furu K, et al. 2015. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 350:h1798. 
• Grzeskowiak LE, et al. 2022. Perinatal antidepressant use and breastfeeding outcomes: Findings from the Norwegian Mother, Father and Child Cohort Study. Acta Obstet Gynecol Scand. 101:344–54 
• Grigoriadis S, et al. 2013. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry.74(4): e309-20. 
• Holland J, Brown R. 2017. Neonatal venlafaxine discontinuation syndrome: A mini-review. Eur J Paediatr Neurol. 21(2):264-8. 
• Ilett KF, et al. 2002. Distribution of venlafaxine and its o-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol. 53:17-22. 
• Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. Acta Paediatr.104(4):384-91. 
• Kolding L, et al. 2021. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG 128(12):1949-1957. 
• Lassen D, et al., 2016. First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: A systematic review. Basic Clin Pharmacol Toxicol. 118(1):32-6. 
• Lennestal R and Kallen B. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 27(6):607-613. 
• Levinson-Castiel R, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 160:173-176. 
• Marks C, et al. 2021. Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study. Pharmacotherapy. 41(11):907-914. 
• Matthys A, et al. 2014. Psychotropic medication use during pregnancy and lactation: Role of ultrasound assessment. Donald Sch J Ultrasound Obstet Gynecol. 8:109-21. 
• Newport DJ, et al. 2009. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J.Clin Psychiatry. 70(9):1304-10. 
• Newport DJ, et al. 2016. Prenatal psychostimulant and antidepressant exposure and risk of hypertensive disorders of pregnancy. J Clin Psychiatry. 77(11):1538-45. 
• Nulman I, et al. 2012. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 169(11):1165-74. 
• Polen KN, et al., National Birth Defects Prevention Study. 2013. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. Birth Defects Res A Clin Mol Teratol.97(1):28-35. 
• Rai D, et al. 2017. Antidepressants during pregnancy and autism in offspring: population-based cohort study. BMJ 358:j2811,  
• Richardson JL, et al. 2019. Pregnancy outcomes following maternal venlafaxine use: a prospective observational comparative cohort study. Reprod Toxicol 84:108-113, 
• Schoretsanitis G, et al. 2019. Antidepressants in breastmilk: comparative analysis of excretion ratios. Arch Womens Ment Health 22(3):383-390. 
• U.S. Food and Drug Administration. 2023. Effexor XR Drug Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf. Accessed 5 March 2026.  
• Wang XY, et al. 2023. Antidepressant use during pregnancy and the risk for gestational diabetes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 36(1):2162817,  
• Wartko PD, et al. 2019. Antidepressant continuation in pregnancy and risk of gestational diabetes. Pharmacoepidemiol Drug Saf 28(9): 1194-1203. 
• Westin AA, et al. 2017. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. PLoS One. 12(7):e0181082. 
• Yue M, et al. 2023. Pharmacokinetics of Antidepressants in Pregnancy. J Clin Pharmacol. 63 Suppl 1: S137-S158.